Biomaterials for Cancer Immunotherapy 2.0
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 1485
Special Issue Editor
Interests: targeted drug delivery; nanoparticles; antibody-drug conjugates; controlled release; chemoprevention; immunotherapy; cancer vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of the previous one, "Biomaterials for Cancer Immunotherapy" https://www.mdpi.com/journal/cancers/special_issues/Biomaterials_Cancer_Immunotherapy.
The goal of cancer immunotherapy is to activate the host immune system to recognize and eliminate malignant cells. The term immunotherapy is used broadly to include various vaccine modalities, cytokines, CAR-T cells, NK cell therapies, antibodies that mediate antibody-dependent cellular cytotoxicity, checkpoint inhibitors, oncolytic viruses, and immunomodulators that reverse tumor-induced immunosuppression. Immunotherapy is highly effective in improving therapeutic outcomes in many tumor types, including melanoma, renal cell carcinoma, bladder cancer, head and neck cancers, and lung cancers. However, only a subset of patients benefit from it, and resistance can develop even in those patients. Further, some immunotherapeutic modalities are associated with serious side effects. There is intense interest in further improving the effectiveness of immunotherapy and overcoming resistance.
Biomaterials can improve the effectiveness of immunotherapy by facilitating selective and improved delivery of the active agent to the target cells and tissue. The enhanced activation of antigen-presenting cells by delivering immunostimulants in nanocarriers and the improved activity of checkpoint inhibitors following local sustained delivery are some examples. The goal of this Special Issue on “Biomaterials for Cancer Immunotherapy 2.0” is to further highlight, through original research articles as well as comprehensive reviews, the use of biomaterials to improve the safety and efficacy of anticancer immunotherapy.
Prof. Dr. Jayanth Panyam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- immunomodulators
- antibodies
- checkpoint inhibitors
- immunosuppression
- cell therapy
